

Publications Guidance for Non-Protocol Team Authors

Updated – 08 August 2022

Language and Other Conventions

- In keeping with HPTN policy, all works (abstracts, presentations, posters and manuscripts) produced from HPTN 071 must include the full name of the study in the title of the work (“HPTN 071 (PopART)”).
- Title of the study should always be written: “HPTN 071 (PopART)” except as below.
- For abstracts, in order to save word count, we may use “HPTN071(PopART)” (no spaces). It is preferable to use the version with spaces if possible. Whichever version is used should be used consistently throughout the abstract.
- The proper way to refer to CHiPs the first time is “Community HIV-care Providers”. The proper way to abbreviate CHiPs is “CHiPs”
- Although we should always refer to the full study/trial as “HPTN 071 (PopART)”, we have agreed that the study’s intervention...the household visits by CHiPs, the additional support provided in the clinics by implementing partners, offering ART universally in Arm A, etc...is called “the PopART intervention”. This is the only time we use “PopART” without “HPTN 071”.
- The official title of the study is “HPTN 071 Population Effects of Antiretroviral Therapy to Reduce HIV Transmission (PopART): A cluster-randomized trial of the impact of a combination prevention package on population-level HIV incidence in Zambia and South Africa”
- We have agreed that study implementation overall (field work) began January 2014 and ended June 2018. Although some activity began in Nov 2013, it was then suspended and recommenced in Jan 2014, so for simplicity, we will say January.
- Delivery of the PopART household intervention began for the study Jan 2014 (in Zambia) and ended for both sites Dec 2017.
- If a journal or conference requires them, the registration and approval numbers for the HPTN 071 study are as follows:
 - Division of AIDS (DAIDS), the study sponsor, has given 071 the **protocol ID number** of: 11865
 - The study has been registered with ClinicalTrials.gov. The registration # is: NCT01900977
 - The following numbers are associated with the trial from the pertinent ethics committees:
 - South Africa- Stellenbosch University Health Research Ethics Committee (HREC) approval number: N12/11/074
 - Zambia- UNZA BREC reference number (not an approval number but a reference number that is given to any submission made whether approved or not):
 - HPTN071/PopART UNZA BREC REF:-011-11-12
 - HPTN071a/Stigma-001-02-14
 - HPTN071-2/Phylogenetics UNZA BREC REF:-004-05-15
 - London- London School of Hygiene and Tropical Medicine (LSHTM) Research Ethics Committee approval number: 6326

Declarations of Funding/Declarations of Competing Interests

It is not possible to standardize guidance for how to complete declarations that are required when submitting a manuscript to a journal, because different journals have different requirements. However, some general tips are:

- A primary concern re: conflicts of interest pertains to industry funding of research. Fortunately, HPTN 071 did not receive funding from industry.
- Even though protocol team authors did not receive payment individually from the study's funders/sponsors, their institutions did receive funding from the study funders/sponsors, which in turn paid for the protocol team members'/authors' work on the study, and so needed to be declared. Depending on the wording of the request, the author may be required to declare only the funding sources that support the work on the study at their institution (or perhaps only the funding to their institution that supports their work as an individual on the study), which may be a sub-set of the funders of the study as a whole.
- Note that different parts of this study have been funded by different sources. Although authors should always recognize the funders from the main trial, additional funding may need to be acknowledged for sub/ancillary studies.

Acknowledgement Language for All Products Developed by Non-Protocol Team Authors

The authors acknowledge the contributions to HPTN 071 (PopART) of the participants in the trial, the study communities, the study investigators and the study's implementing partners in South Africa (City of Cape Town and Western Cape Government health departments, Kheth' Impilo, ANOVA Healthcare, SACTWU Worker Health Programme and Supply Chain Management Services) and Zambia (Zambian Ministry of Health, CIDRZ, ZPCT II and JSI).

HPTN 071 was sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), with funding from the U.S. President's Emergency Plan for AIDS Relief (PEPFAR). Additional funding was provided by the International Initiative for Impact Evaluation (3ie) with support from the Bill & Melinda Gates Foundation, as well as by NIAID, the National Institute on Drug Abuse (NIDA) and the National Institute of Mental Health (NIMH), all part of NIH.

The following sub-studies of the HPTN 071 (PopART) study should include additional acknowledgement:

- Adolescent (P-ART-Y) study:
 - *EVIDENCE FOR HIV PREVENTION IN SOUTHERN AFRICA (ehpsa) with funding from the UK DFID and Sweden*
- HIV Self-Testing:
 - *International Initiative for Impact Evaluation (3ie)*
- Stigma:
 - *U.S. National Institute of Mental Health (NIMH)*
- Phylogeny:
 - *U.S. National Institute of Mental Health (NIMH)*